Health TrialsbyHealthPanel

A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China

ConditionGraves´ Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFirst Hospital of China Medical University

About this trial

This study was a prospective follow-up study of newly diagnosed and relapsed Graves' disease patients in the Endocrinology Clinic of the First Affiliated Hospital of China Medical University. The following aspects will be studied: 1. Through the prospective follow-up study of GD patients, we will get the relapse rate and remission rate of GD patients treated with drugs, explore the risk factors of GD patients relapsing after drug treatment, and make GD relapse risk prediction software; 2. To compare the effects of high dose and low dose methimazole on the remission rate, liver side effects, leukopenia and other adverse drug reactions, and to summarize the incidence and risk factors of liver side effects, leukopenia and other adverse drug reactions caused by drug treatment; 3. To investigate the sensitivity and specificity of TRAb in the diagnosis of GD in China and its role in predicting recurrence; 4. After taking ATD, the serum alkaline phosphatase of GD patients will increase first and then decrease. This study will focus on analyzing the dynamic changes of this index before and after methimazole treatment, and analyze the relationship between it and thyroid function index.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years old.

Newly diagnosed GD and GD relapses.

Disqualifiers

Patients with active infiltrative exophthalmos in GD were excluded.

Patients with other autoimmune diseases affecting thyroid function were excluded.

Excluding patients with combined malignancies and other serious diseases.

Trial population

The study population includes male and female hyperthyroidism patients over the age of 18. Participants must have no history of autoimmune hepatitis, viral hepatitis, blood disease, bone marrow or liver transplantation, and complete clinical data.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Methimazole(MMI)

    Drug

    Determine the enrolled GD patients and adjust the dosage of methimazole according to the 2016 American Thyroid Association guidelines. Conduct thyroid function, liver function, TRAb, and blood routine tests during outpatient follow-up to observe the treatment effect and provide medication guidance.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Relapse and remission of Graves' disease in adult treated with methimazole.

Relapse was defined as having clinical and biochemical hyperthyroidism (FT3 and FT4 increased and TSH decreased) after discontinuation of methimazole. Remission is defined as having clinical and biochemical euthyroidism(FT3, FT4 and TSH are normal) without methimazole treatment for at least 12 months. Through the prospective follow-up study of GD patients, we will get the relapse rate and remission rate of GD patients treated with drugs, explore the risk factors of GD patients relapsing after drug treatment, and make GD relapse risk prediction software.

Time frame
30 years
2

Adverse effects of methimazole in the treatment of Graves' disease in adult.

Adverse effects are defined as having neutropenia (absolute neutrophil count\< 1800/µL), liver dysfunction (AST or ALT\> 60 IU/L), rash, arthralgia, myalgia, et al. To compare the effects of high dose and low dose methimazole on the remission rate, liver side effects, leukopenia and other adverse drug reactions, and to summarize the incidence and risk factors of liver side effects, leukopenia and other adverse drug reactions caused by drug treatment

Time frame
30 years

Secondary outcomes

1

Thyrotropin receptor antibody(TRAb)

To investigate the sensitivity and specificity of the thyrotropin receptor antibody(TRAb) in the diagnosis of GD in China and its role in predicting recurrence

Time frame
30 years
2

The serum alkaline phosphatase

After taking ATD, the serum alkaline phosphatase of GD patients will increase first and then decrease. This study will focus on analyzing the dynamic changes of this index before and after methimazole treatment, and analyze the relationship between it and thyroid function index

Time frame
30 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Hospital of China Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now